Hamieh Mohamad, Nassereddine Zahra, Moussa Malek, Al Ali Firas, Dbouk Mohamad, Saab Mohamad
Department of Cardiology, Beirut Cardiac Institute, Beirut, Lebanon.
Department of Cardiovascular Surgery, Beirut Cardiac Institute, Beirut, Lebanon.
Oxf Med Case Reports. 2023 Oct 23;2023(10):omad086. doi: 10.1093/omcr/omad086. eCollection 2023 Oct.
De novo aortic regurgitation (AR) presents a great challenge following left ventricular assist device (LVAD) implantation and requires valve replacement in some cases. Patients with LVAD are frequently those who underwent multiple previous sternotomies or suffer from multiple comorbidities. Thus, they are at high surgical risk for further sternotomy. Transcatheter aortic valve implantation (TAVI) previously approved for treatment of severe aortic stenosis is also used for this category of patients. Here, we report the case of a young female patient supported with heart mate II LVAD who presented with severe de novo AR. The patient was successfully treated with TAVI using Myval trancatheter heart valve (THV) in our center. To our knowledge, our patient is the first to be treated with such type of valve using TAVI procedure in LVAD supported patients.
植入左心室辅助装置(LVAD)后,新发主动脉瓣反流(AR)带来了巨大挑战,在某些情况下需要进行瓣膜置换。LVAD患者通常是那些之前接受过多次胸骨切开术或患有多种合并症的人。因此,他们接受进一步胸骨切开术的手术风险很高。先前被批准用于治疗严重主动脉瓣狭窄的经导管主动脉瓣植入术(TAVI)也用于这类患者。在此,我们报告一例接受HeartMate II LVAD支持的年轻女性患者,该患者出现严重新发AR。在我们中心,该患者使用Myval经导管心脏瓣膜(THV)通过TAVI成功治疗。据我们所知,我们的患者是首例在LVAD支持的患者中使用此类瓣膜通过TAVI手术进行治疗的。